Payment overview · 2025
General Payments
$178.41
10 reported records · 5 companies
Healthcare provider profile · identity verified
Brett O Brown, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBUS, MS · NPI 1841221702
Verified facts
What the public records show
CMS Open Payments records show Brett O Brown, MD received $178.41 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 33.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.28 | 33.2% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $54.91 | 30.8% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.40 | 15.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.55 | 11.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.27 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $178.41 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $54.91 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.13 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.15 | 2 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $27.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 981 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 971 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 964 | 171 |
| Omeprazole | Omeprazole | 923 | 126 |
| Gabapentin | Gabapentin | 694 | 78 |
| Lisinopril | Lisinopril | 648 | 127 |
| Losartan Potassium | Losartan Potassium | 613 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 505 | 95 |
| Potassium Chloride | Potassium Chloride | 469 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 463 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 436 | 77 |
| Meloxicam | Meloxicam | 427 | 78 |
| Furosemide | Furosemide | 401 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 387 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 377 | 61 |
| Simvastatin | Simvastatin | 360 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 289 | 55 |
| Montelukast Sodium | Montelukast Sodium | 286 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 281 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 280 | 54 |
| Hydralazine Hcl | Hydralazine Hcl | 265 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 263 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 257 | 47 |
| Carvedilol | Carvedilol | 250 | 44 |
| Metformin Hcl | Metformin Hcl | 249 | 69 |
| Allopurinol | Allopurinol | 248 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 226 | 57 |
| Glipizide Er | Glipizide | 225 | 53 |
| Alprazolam | Alprazolam | 223 | 47 |
| Donepezil Hcl | Donepezil Hcl | 212 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 199 | 27 |
| Trazodone Hcl | Trazodone Hcl | 190 | 21 |
| Metformin Hcl Er | Metformin Hcl | 183 | 50 |
| Bupropion Xl | Bupropion Hcl | 179 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 178 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 20 |
| Clonazepam | Clonazepam | 170 | 29 |
| Alendronate Sodium | Alendronate Sodium | 159 | suppressed |
| Eliquis | Apixaban | 157 | 20 |
| Sertraline Hcl | Sertraline Hcl | 157 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 155 | 42 |
| Mirtazapine | Mirtazapine | 150 | 24 |
| Divalproex Sodium | Divalproex Sodium | 142 | 18 |
| Valsartan | Valsartan | 140 | 30 |
| Famotidine | Famotidine | 137 | 25 |
| Spironolactone | Spironolactone | 125 | 19 |
| Methylprednisolone | Methylprednisolone | 119 | 101 |
| Benazepril Hcl | Benazepril Hcl | 117 | 26 |
| Bumetanide | Bumetanide | 117 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 25 |
| Atenolol | Atenolol | 109 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 106 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | suppressed |
| Xarelto | Rivaroxaban | 105 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 100 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 26 |
| Glipizide | Glipizide | 95 | 21 |
| Finasteride | Finasteride | 92 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 31 |
| Olanzapine | Olanzapine | 83 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 82 | suppressed |
| Entresto | Sacubitril/Valsartan | 81 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 81 | 18 |
| Pregabalin | Pregabalin | 81 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 77 | 14 |
| Levetiracetam | Levetiracetam | 75 | suppressed |
| Lorazepam | Lorazepam | 74 | 14 |
| Myrbetriq | Mirabegron | 74 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 73 | 14 |
| Lamotrigine | Lamotrigine | 72 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 71 | suppressed |
| Lansoprazole | Lansoprazole | 70 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 18 |
| Jardiance | Empagliflozin | 69 | suppressed |
| Prednisone | Prednisone | 67 | 12 |
| Warfarin Sodium | Warfarin Sodium | 67 | 15 |
| Ozempic | Semaglutide | 66 | 12 |
| Cefdinir | Cefdinir | 62 | 54 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 15 |
| Temazepam | Temazepam | 60 | 12 |
| Sucralfate | Sucralfate | 59 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 55 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 29 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 52 | suppressed |
| Sotalol | Sotalol Hcl | 51 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | suppressed |
| Estradiol | Estradiol | 50 | 12 |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 48 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 48 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 39 |
| Cephalexin | Cephalexin | 46 | suppressed |
| Torsemide | Torsemide | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | suppressed |
| Irbesartan | Irbesartan | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 45 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 15 |
| Cinacalcet Hcl | Cinacalcet Hcl | 43 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 12 |
| Risperidone | Risperidone | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 26 |
| Creon | Lipase/Protease/Amylase | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 12 |
| Naproxen | Naproxen | 29 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 11 |
| Fluconazole | Fluconazole | 27 | 16 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 27 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 19 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Trimethoprim | Trimethoprim | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 15 |
| Linzess | Linaclotide | 23 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Triazolam | Triazolam | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $178.41 · 10 records | Amgen Inc. | CDS - MCT/CEM Monitoring, Dexcom G6 Transmitter, EVENITY, JARDIANCE, MOUNJARO, OTEZLA, REPATHA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error